The ADNI-3 Study - RECRUITING
The study is open to:
both male and female subjects
aged 55-90 years
cognitively normal, have Mild Cognitive Impairment (MCI) or have been diagnosed with mild dementia due to Alzheimer’s
CN: MMSE 24-30, CDR 0/ MCI: MMSE 24-30, CDR 0.5/ Mild AD: MMSE 20-24, CDR 0.5-1.0
This study is sponsored by the NIH. ADNI 3 (Alzheimer’s Disease Neuroimaging Initiative) historic study of brain aging which could help change the future of Alzheimer’s disease. ADNI’s unprecedented approach to research is intended to encourage new investigation and to increase the pace of discovery in the race to prevent, treat and one-day cure Alzheimer’s disease. Poor memory is often viewed as a simple sign of getting older, complicating our understanding and treatment of Alzheimer's disease. For more than a decade, ADNI researchers have worked tirelessly to better understand the disease and its progression in a way that will help the development of future treatment options. No experimental medication will be involved.
For information about participation in the ADNI-3 study, please contact Dr. Antero Sarreal at 845-398-6532, or at Antero.Sarreal@nki.rfmh.org.
For more detailed information about the study and study drug please click here.